{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T20:26:16Z","timestamp":1773865576940,"version":"3.50.1"},"reference-count":35,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"vor","delay-in-days":1461,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1038\/ki.2013.285","type":"journal-article","created":{"date-parts":[[2013,7,31]],"date-time":"2013-07-31T12:39:11Z","timestamp":1375274351000},"page":"1278-1286","source":"Crossref","is-referenced-by-count":81,"title":["Short-term renal hemodynamic effects of tolvaptan in subjects with autosomal dominant polycystic kidney disease at various stages of chronic kidney disease"],"prefix":"10.1016","volume":"84","author":[{"given":"Wendy E.","family":"Boertien","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esther","family":"Meijer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul E.","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan J.L.","family":"Bakker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank S.","family":"Czerwiec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joachim","family":"Struck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorothee","family":"Oberdhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan E.","family":"Shoaf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Holly B.","family":"Krasa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ron T.","family":"Gansevoort","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1038\/ki.2013.285_bb0010","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/S0140-6736(07)60601-1","article-title":"Autosomal dominant polycystic kidney disease","volume":"369","author":"Torres","year":"2007","journal-title":"Lancet"},{"key":"10.1038\/ki.2013.285_bb0015","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1111\/j.1523-1755.2004.00843.x","article-title":"Cyclic AMP promotes growth and secretion in human polycystic kidney epithelial cells","volume":"66","author":"Belibi","year":"2004","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2013.285_bb0020","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1046\/j.1523-1755.2003.00242.x","article-title":"Lillian Jean Kaplan international prize for advancement in the understanding of polycystic kidney disease. understanding polycystic kidney disease: a systems biology approach","volume":"64","author":"Grantham","year":"2003","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2013.285_bb0025","doi-asserted-by":"crossref","first-page":"F1005","DOI":"10.1152\/ajprenal.00243.2011","article-title":"Tolvaptan inhibits ERK-dependent cell proliferation, cl secretion, and in vitro cyst growth of human ADPKD cells stimulated by vasopressin","volume":"301","author":"Reif","year":"2011","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1038\/ki.2013.285_bb0030","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.2215\/CJN.03530411","article-title":"Tolvaptan in autosomal dominant polycystic kidney disease: three years\u2019 experience","volume":"6","author":"Higashihara","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1038\/ki.2013.285_bb0035","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1681\/ASN.2004121090","article-title":"Effectiveness of vasopressin V2 receptor antagonists OPC\u201331260 and OPC\u201341061 on polycystic kidney disease development in the PCK rat","volume":"16","author":"Wang","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/ki.2013.285_bb0040","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/nm1004","article-title":"Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease","volume":"10","author":"Torres","year":"2004","journal-title":"Nat Med"},{"key":"10.1038\/ki.2013.285_bb0045","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1093\/ndt\/gfr069","article-title":"Therapeutic potential of vasopressin V2 receptor antagonist in a mouse model for autosomal dominant polycystic kidney disease: optimal timing and dosing of the drug","volume":"26","author":"Meijer","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1038\/ki.2013.285_bb0050","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1038\/nm935","article-title":"Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist","volume":"9","author":"Gattone","year":"2003","journal-title":"Nat Med"},{"key":"10.1038\/ki.2013.285_bb0055","first-page":"860","article-title":"OPC\u201341061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats","volume":"287","author":"Yamamura","year":"1998","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1038\/ki.2013.285_bb0060","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/ki.2011.119","article-title":"Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease","volume":"80","author":"Irazabal","year":"2011","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2013.285_bb0065","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1053\/j.ajkd.2010.11.029","article-title":"Rationale and design of the TEMPO (tolvaptan efficacy and safety in management of autosomal dominant polycystic kidney disease and its outcomes) 3\u20134 study","volume":"57","author":"Torres","year":"2011","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/ki.2013.285_bb0070","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1038\/ki.2013.285_bb0075","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1373\/clinchem.2005.060038","article-title":"Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin","volume":"52","author":"Morgenthaler","year":"2006","journal-title":"Clin Chem"},{"key":"10.1038\/ki.2013.285_bb0080","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.tem.2007.11.001","article-title":"Copeptin: clinical use of a new biomarker","volume":"19","author":"Morgenthaler","year":"2008","journal-title":"Trends Endocrinol Metab"},{"key":"10.1038\/ki.2013.285_bb0085","doi-asserted-by":"crossref","first-page":"F274","DOI":"10.1152\/ajprenal.1989.256.2.F274","article-title":"Renal microvascular effects of vasopressin and vasopressin antagonists","volume":"256","author":"Edwards","year":"1989","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1038\/ki.2013.285_bb0090","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/1056-8727(95)80033-B","article-title":"Effect of AVP V1-receptor antagonist on urinary albumin excretion and renal hemodynamics in NIDDM nephropathy: role of AVP V1-receptor","volume":"9","author":"Yamada","year":"1995","journal-title":"J Diab Comp"},{"key":"10.1038\/ki.2013.285_bb0095","doi-asserted-by":"crossref","first-page":"F100","DOI":"10.1152\/ajprenal.00088.2008","article-title":"Vasopressin regulates the renin-angiotensin-aldosterone system via V1a receptors in macula densa cells","volume":"295","author":"Aoyagi","year":"2008","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1038\/ki.2013.285_bb0100","doi-asserted-by":"crossref","first-page":"F819","DOI":"10.1152\/ajprenal.1984.246.6.F819","article-title":"Influence of vasopressin on renal hemodynamics in conscious Brattleboro rats","volume":"246","author":"Gellai","year":"1984","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1038\/ki.2013.285_bb0105","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1681\/ASN.V76842","article-title":"Vasopressin increases glomerular filtration rate in conscious rats through its antidiuretic action","volume":"7","author":"Bouby","year":"1996","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/ki.2013.285_bb0110","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/ki.1981.160","article-title":"Mechanisms of action of various hormones and vasoactive substances on glomerular ultrafiltration in the rat","volume":"20","author":"Schor","year":"1981","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2013.285_bb0115","first-page":"F521","article-title":"Tubuloglomerular feedback during elevated renal venous pressure","volume":"249","author":"Boberg","year":"1985","journal-title":"Am J Physiol"},{"key":"10.1038\/ki.2013.285_bb0120","doi-asserted-by":"crossref","first-page":"e32533","DOI":"10.1371\/journal.pone.0032533","article-title":"Measuring and estimating GFR and treatment effect in ADPKD patients: results and implications of a longitudinal cohort study","volume":"7","author":"Ruggenenti","year":"2012","journal-title":"PLoS One"},{"key":"10.1038\/ki.2013.285_bb0125","doi-asserted-by":"crossref","first-page":"150","DOI":"10.5414\/CP201621","article-title":"Absolute bioavailability of tolvaptan and determination of minimally effective concentrations in healthy subjects","volume":"50","author":"Shoaf","year":"2012","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1038\/ki.2013.285_bb0130","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/j.1365-2125.2011.04114.x","article-title":"Effects of CYP3A4 inhibition and induction on the pharmacokinetics and pharmacodynamics of tolvaptan, a non-peptide AVP antagonist in healthy subjects","volume":"73","author":"Shoaf","year":"2012","journal-title":"Br J Clin Pharmacol"},{"key":"10.1038\/ki.2013.285_bb0135","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1177\/0091270007307877","article-title":"Pharmacokinetics, pharmacodynamics, and safety of tolvaptan, a nonpeptide AVP antagonist, during ascending single-dose studies in healthy subjects","volume":"47","author":"Shoaf","year":"2007","journal-title":"J Clin Pharmacol"},{"key":"10.1038\/ki.2013.285_bb0140","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S0140-6736(94)92026-5","article-title":"Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease 1","volume":"343","author":"Ravine","year":"1994","journal-title":"Lancet"},{"key":"10.1038\/ki.2013.285_bb0145","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","article-title":"A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. modification of diet in renal disease study group","volume":"130","author":"Levey","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1038\/ki.2013.285_bb0150","unstructured":"Boertien WE, Meijer E, de Jong PE et al. Short-term effects on efficacy parameters with tolvaptan in subjects with ADPKD at various levels of kidney function. In progress."},{"key":"10.1038\/ki.2013.285_bb0155","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJM198710223171717","article-title":"Simplified calculation of body-surface area","volume":"317","author":"Mosteller","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1038\/ki.2013.285_bb0160","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1681\/ASN.V74567","article-title":"Precision of glomerular filtration rate determinations for long-term slope calculations is improved by simultaneous infusion of 125I-iothalamate and 131I-hippuran","volume":"7","author":"Apperloo","year":"1996","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/ki.2013.285_bb0165","first-page":"97","article-title":"A radioisotope method for simultaneous determination of the glomerular filtration rate and the effective renal plasma flow","volume":"20","author":"Donker","year":"1977","journal-title":"Neth J Med"},{"key":"10.1038\/ki.2013.285_bb0170","doi-asserted-by":"crossref","first-page":"337","DOI":"10.5414\/CNP72337","article-title":"Glomerular filtration rate measurements by 125I-iothalamate should be corrected for inaccurate urine collections with 131I-hippuran","volume":"72","author":"Michels","year":"2009","journal-title":"Clin Nephrol"},{"key":"10.1038\/ki.2013.285_bb0175","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1038\/ki.2013.285_bb0180","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa1114248","article-title":"Estimating glomerular filtration rate from serum creatinine and cystatin C","volume":"367","author":"Inker","year":"2012","journal-title":"N Engl J Med"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253815561188?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253815561188?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T16:58:28Z","timestamp":1646240308000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253815561188"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["S0085253815561188"],"URL":"https:\/\/doi.org\/10.1038\/ki.2013.285","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12]]}}}